IL4 and non-Hodgkin lymphoma: Consistent with experiments using Z199, monalizumab significantly increased specific lysis (Fig. 6a and b) and IFNγ secretion (Fig. 6c) against NHL cells treated with CD40L and IL-4 in both the presence and absence of rituximab.